Lake Medical Imaging has been selected to participate in the American College of Radiology (ACR) Contrast Enhanced Mammography Imaging Screening Trial (CMIST) in collaboration with the Breast Cancer Research Foundation (BCRF) and GE Healthcare. The trial seeks to determine whether contrast-enhanced mammography (CEM) improves breast cancer detection and reduces false positive exams in women with dense breasts.
CEM combines mammography and vascular-based screening methods in a simple and quick procedure to highlight areas of unusual blood flow patterns that may indicate malignancy.
Specifically, CMIST seeks to determine if CEM is more accurate in detecting breast cancer compared
to digital breast tomosynthesis in women with dense breasts. One of the goals of the study of
contrast mammography is the potential to develop more individualized breast imaging strategies for
women with dense breasts, which ACR reports represents 43 percent of women aged 40 to 72.
This is a well-timed study, given the US Food and Drug Administration’s recent letter to U.S.
Congresswoman Rosa DeLauro that the agency expects to finalize its breast density notification rules by year end 2022 or early next year. As a result, more women will be made aware of their breast density status — a good outcome.